NYSE:SNY - Sanofi Stock Price, Price Target & More

$39.96 -0.20 (-0.50 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$39.96
Today's Range$39.91 - $40.14
52-Week Range$38.14 - $50.65
Volume1.39 million shs
Average Volume1.80 million shs
Market Capitalization$101.98 billion
P/E Ratio12.77
Dividend Yield2.70%
Beta0.85

About Sanofi (NYSE:SNY)

Sanofi logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.

Receive SNY News and Ratings via Email

Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:SNY
CUSIPN/A
Phone33-1-53-77-44-00

Debt

Debt-to-Equity Ratio0.25%
Current Ratio1.70%
Quick Ratio1.26%

Price-To-Earnings

Trailing P/E Ratio12.77
Forward P/E Ratio12.04
P/E Growth2.04

Sales & Book Value

Annual Sales$39.60 billion
Price / Sales2.53
Cash Flow$4.6901 per share
Price / Cash8.52
Book Value$26.11 per share
Price / Book1.53

Profitability

EPS (Most Recent Fiscal Year)$3.13
Net Income$4.28 billion
Net Margins23.25%
Return on Equity24.30%
Return on Assets13.98%

Miscellaneous

Employees106,859
Outstanding Shares2,508,090,000

How to Become a New Pot Stock Millionaire

Sanofi (NYSE:SNY) Frequently Asked Questions

What is Sanofi's stock symbol?

Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY."

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Tuesday, February 13th. Stockholders of record on Thursday, May 10th will be given a dividend of $1.8609 per share on Monday, June 4th. This represents a dividend yield of 4.72%. The ex-dividend date is Wednesday, May 9th. This is a boost from Sanofi's previous annual dividend of $1.58. View Sanofi's Dividend History.

How were Sanofi's earnings last quarter?

Sanofi SA (NYSE:SNY) issued its earnings results on Wednesday, February, 7th. The company reported $0.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.69 by $0.07. The business earned $8.69 billion during the quarter, compared to analysts' expectations of $8.65 billion. Sanofi had a return on equity of 24.30% and a net margin of 23.25%. The company's revenue for the quarter was down 2.1% compared to the same quarter last year. During the same period last year, the business posted $1.25 EPS. View Sanofi's Earnings History.

When is Sanofi's next earnings date?

Sanofi is scheduled to release their next quarterly earnings announcement on Friday, April, 27th 2018. View Earnings Estimates for Sanofi.

What price target have analysts set for SNY?

12 brokers have issued 1 year target prices for Sanofi's stock. Their predictions range from $45.00 to $55.00. On average, they expect Sanofi's share price to reach $49.3333 in the next year. View Analyst Ratings for Sanofi.

What are Wall Street analysts saying about Sanofi stock?

Here are some recent quotes from research analysts about Sanofi stock:
  • 1. According to Zacks Investment Research, "Sanofi’s Diabetes franchise is under significant pressure with key product, Lantus facing increasing competitive pressure at the payor level and the presence of biosimilar competition in several European markets and Japan. The declining trends in the diabetes franchise are expected to continue in 2018. Meanwhile, the performance of the Consumer Healthcare franchise was soft in 2017. Moreover, Sanofi’s shares have underperformed the industry this year so far. Other headwinds include generic competition and slower-than-expected uptake of new products like Praluent. However, Sanofi's focus on streamlining its business and pursuing business development deals is encouraging. Further, the acquisitions of Ablynx and Bioverativ are expected to strengthen Sanofi’s position in the rare blood disorders market. Sanofi has a mixed record of earnings surprises in recent quarters. Estimates movement has been mixed ahead of Q1 results." (4/17/2018)
  • 2. Argus analysts commented, "The company also has a strong new drug pipeline that includes Toujeo, a next-generation insulin product, and dipilumab, for atopic dermatitis and other inflammatory conditions," the analyst said.See also: Where Does Zika Virus Vaccine Research Stand Now? FY18 ExpectationsArgus expects the company's 2017 revenues from continuing operations to benefit from the recent acquisition of Boehringer Ingelheim's consumer health business and higher sales of multiple sclerosis products. At the same time, the firm expects reduced diabetes drug sales.The firm also sees margin pressure due to pricing pressures for diabetes products in the U.S. and costs related to the launch of Dupixent and Kevzara, partly offset by a sales force reorganization and other cost-savings initiatives."In 2018, we expect continued solid demand for multiple sclerosis drugs and increased sales in emerging markets to outweigh weaker sales of diabetes drugs, and look for the company's cost-savings program to benefit margins," (9/1/2017)

Who are some of Sanofi's key competitors?

Who are Sanofi's key executives?

Sanofi's management team includes the folowing people:
  • Serge Weinberg, Independent Chairman of the Board (Age 66)
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director (Age 61)
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee (Age 59)
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel; Member of the Executive Committee (Age 58)
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets; Member of the Executive Committee (Age 54)
  • Roberto Pucci, Executive Vice President, Human Resources; Member of the Executive Committee (Age 53)
  • Dominique Carouge, Executive Vice President - Head of Business Transformation Member of the Executive Committee
  • Peter Guenter, Executive Vice President, Diabetes & Cardiovascular; Member of the Executive Committee (Age 55)
  • David Loew, Executive Vice President, Sanofi Pasteur; Member of the Executive Committee
  • Philippe Luscan, Executive Vice President, Global Industrial Affairs; Member of the Executive Committee (Age 55)

Has Sanofi been receiving favorable news coverage?

Press coverage about SNY stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sanofi earned a media sentiment score of 0.17 on Accern's scale. They also assigned headlines about the company an impact score of 45.36 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Sanofi?

Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sanofi's stock price today?

One share of SNY stock can currently be purchased for approximately $39.96.

How big of a company is Sanofi?

Sanofi has a market capitalization of $101.98 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. Sanofi employs 106,859 workers across the globe.

How can I contact Sanofi?

Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected]


MarketBeat Community Rating for Sanofi (SNY)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  287 (Vote Outperform)
Underperform Votes:  388 (Vote Underperform)
Total Votes:  675
MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sanofi (NYSE:SNY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
12 Wall Street analysts have issued ratings and price targets for Sanofi in the last 12 months. Their average twelve-month price target is $49.3333, suggesting that the stock has a possible upside of 23.46%. The high price target for SNY is $55.00 and the low price target for SNY is $45.00. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.082.002.092.30
Ratings Breakdown: 2 Sell Rating(s)
7 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
7 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $49.3333$49.3333$51.50$53.50
Price Target Upside: 23.46% upside21.54% upside15.01% upside9.71% upside

Sanofi (NYSE:SNY) Consensus Price Target History

Price Target History for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/16/2018Deutsche BankReiterated RatingBuyLowView Rating Details
3/23/2018Liberum CapitalUpgradeHold -> BuyLowView Rating Details
2/8/2018Sanford C. BernsteinReiterated RatingMarket Perform$50.00 -> $45.00LowView Rating Details
1/23/2018BarclaysDowngradeEqual Weight -> UnderweightLowView Rating Details
1/15/2018UBSReiterated RatingNeutralLowView Rating Details
1/11/2018JPMorgan ChaseReiterated RatingNeutralLowView Rating Details
1/2/2018Nord/LBReiterated RatingNeutralLowView Rating Details
12/18/2017CowenSet Price TargetHold$48.00LowView Rating Details
12/6/2017Bank of AmericaDowngradeBuy -> NeutralLowView Rating Details
12/1/2017Morgan StanleyDowngradeOverweight -> UnderweightLowView Rating Details
9/1/2017ArgusReiterated RatingBuy$55.00MediumView Rating Details
5/11/2017Berenberg BankDowngradeBuy -> HoldLowView Rating Details
2/9/2017NatixisUpgradeNeutral -> BuyN/AView Rating Details
1/10/2017Leerink SwannReiterated RatingOutperformN/AView Rating Details
1/8/2017Goldman SachsReiterated RatingHoldN/AView Rating Details
9/23/2016Piper JaffrayInitiated CoverageNeutralN/AView Rating Details
9/14/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
9/13/2016BNP ParibasUpgradeUnderperform -> NeutralN/AView Rating Details
6/28/2016CitigroupReiterated RatingNeutralN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Sanofi (NYSE:SNY) Earnings History and Estimates Chart

Earnings by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) Earnings Estimates

Current Year EPS Consensus Estimate: $3.32 EPS
Next Year EPS Consensus Estimate: $3.57 EPS

Sanofi (NYSE SNY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2018$0.84N/AView Earnings Details
2/7/2018Q4 2017$0.69$0.62$8.6474 billion$8.6910 billionViewListenView Earnings Details
11/2/2017Q3 2017$1.00$1.00$10.9322 billion$10.6349 billionViewN/AView Earnings Details
7/31/20176/30/2017$0.74$0.74$8.7078 billion$8.6630 billionViewN/AView Earnings Details
4/28/20173/31/2017$0.73$0.76$8.4033 billion$8.6480 billionViewN/AView Earnings Details
2/8/2017Q416$0.66$0.67$9.87 billion$8.8760 billionViewN/AView Earnings Details
10/28/2016Q3 2016$0.86$1.00$10.9850 billion$10.0711 billionViewN/AView Earnings Details
7/29/2016Q2 2016$0.74$0.74$10.2007 billion$9.1966 billionViewN/AView Earnings Details
4/29/2016Q1 2016$0.72$0.74$9.7608 billion$9.4234 billionViewN/AView Earnings Details
2/9/2016Q4 2015$0.69$0.72$10.5674 billion$10.0666 billionViewN/AView Earnings Details
10/29/2015Q315$0.8750$0.89$10.9740 billion$10.6690 billionViewN/AView Earnings Details
7/30/2015Q2 2015$0.72$0.78$10.1178 billion$10.3749 billionViewN/AView Earnings Details
4/30/2015Q115$0.61$0.73$9.2130 billion$9.7803 billionViewN/AView Earnings Details
2/5/2015Q4$0.89$0.79$11.3425 billion$10.3867 billionViewN/AView Earnings Details
10/28/2014Q3 2014$0.94$0.94$12.0653 billion$11.1463 billionViewN/AView Earnings Details
7/31/2014Q2$0.79$0.72$11.1890 billion$10.8189 billionViewN/AView Earnings Details
4/29/2014Q114$0.84$0.81$11.1915 billion$10.8805 billionViewN/AView Earnings Details
2/6/2014Q4$0.88$0.93$11.3433 billion$11.4381 billionViewN/AView Earnings Details
10/30/2013$1.01$0.93$11.8267 billion$11.5891 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.89$0.73$11.1582 billion$10.5990 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.89$0.80$10.9992 billion$10.6034 billionViewN/AView Earnings Details
2/7/2013Q4 2012$0.77$0.78ViewN/AView Earnings Details
10/25/2012Q3 2012$0.99$1.10ViewN/AView Earnings Details
7/26/2012Q2 2012$0.84$0.90ViewN/AView Earnings Details
4/27/2012Q1 2012$1.13$1.22ViewN/AView Earnings Details
2/8/2012Q4 2011$1.00$1.02ViewN/AView Earnings Details
11/3/2011Q3 2011$1.21$1.24ViewN/AView Earnings Details
7/28/2011Q2 2011$1.18$0.56ViewN/AView Earnings Details
4/28/2011Q1 2011$1.16$1.22ViewN/AView Earnings Details
2/9/2011Q4 2010$0.95$0.96ViewN/AView Earnings Details
10/28/2010Q3 2010$1.17$1.30ViewN/AView Earnings Details
7/29/2010Q2 2010$1.08$0.85ViewN/AView Earnings Details
4/29/2010Q1 2010$1.18$1.23ViewN/AView Earnings Details
2/10/2010Q4 2009$0.92$0.94ViewN/AView Earnings Details
10/30/2009Q3 2009$1.21$1.26ViewN/AView Earnings Details
7/29/2009Q2 2009$1.04$1.24ViewN/AView Earnings Details
4/29/2009Q1 2009$0.86$1.08ViewN/AView Earnings Details
2/11/2009Q4 2008$0.82$0.82ViewN/AView Earnings Details
10/31/2008Q3 2008$0.97$1.07ViewN/AView Earnings Details
7/31/2008Q2 2008$1.07$1.04ViewN/AView Earnings Details
4/30/2008Q1 2008$2.48$2.14ViewN/AView Earnings Details
2/12/2008Q4 2007$0.76$0.82ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sanofi (NYSE:SNY) Dividend Information

Sanofi pays an annual dividend of $1.10 per share, with a dividend yield of 2.75%. SNY's next annual dividend payment will be made on Monday, June 4. Sanofi pays out 35.14% of its earnings out as a dividend.
Next Dividend:6/4/2018
Annual Dividend:$1.10
Dividend Yield:2.75%
Dividend Growth:-4.90% (3 Year Average)
Payout Ratio:35.14% (Trailing 12 Months of Earnings)
33.13% (Based on This Year's Estimates)
30.81% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE:SNY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/13/2018annual$1.86094.72%5/9/20185/10/20186/4/2018
2/17/2017annual$1.57713.65%5/11/20175/15/20176/7/2017
2/22/2016Annual$1.10105/5/20165/9/20166/1/2016
2/26/2015special$1.61813.91%5/6/20155/8/20156/2/2015
(Data available from 1/1/2013 forward)

Insider Trades

Sanofi (NYSE SNY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.00%
Institutional Ownership Percentage: 8.98%
Insider Trading History for Sanofi (NYSE:SNY)
Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Sanofi (NYSE SNY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2017SanofiMajor ShareholderBuy105,820$482.04$51,009,472.80View SEC Filing  
8/23/2017SanofiMajor ShareholderBuy60,595$478.98$29,023,793.10View SEC Filing  
7/9/2014SanofiMajor ShareholderBuy195,000$308.27$60,112,650.00View SEC Filing  
7/8/2014SanofiMajor ShareholderBuy153,000$311.67$47,685,510.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sanofi (NYSE SNY) News Headlines

Source:
DateHeadline
More Than 25 Data Presentations from Sanofi Genzymes Multiple Sclerosis Franchise to Be Featured at AANMore Than 25 Data Presentations from Sanofi Genzyme's Multiple Sclerosis Franchise to Be Featured at AAN
www.businesswire.com - April 20 at 8:38 AM
Sanofi (SNY) to Release Earnings on FridaySanofi (SNY) to Release Earnings on Friday
www.americanbankingnews.com - April 20 at 1:20 AM
Sanofi (SNY) CFO Jerome Contamine to Step Down Later This Year, Informed Company of Plans to Retire - Bloomberg ...Sanofi (SNY) CFO Jerome Contamine to Step Down Later This Year, Informed Company of Plans to Retire - Bloomberg ...
www.streetinsider.com - April 18 at 8:30 AM
Sanofi CFO Jerome Contamine to exit later in 2018Sanofi CFO Jerome Contamine to exit later in 2018
www.marketwatch.com - April 18 at 8:30 AM
UPDATE 2-Sanofi in talks to sell generics arm to Advent for $2.4 blnUPDATE 2-Sanofi in talks to sell generics arm to Advent for $2.4 bln
www.lse.co.uk - April 17 at 5:44 PM
Sanofi (SNY) Lowered to "Sell" at Zacks Investment ResearchSanofi (SNY) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 11:37 AM
Sanofi in talks to sell generics arm Zentiva to Advent for 1.9 billion eurosSanofi in talks to sell generics arm Zentiva to Advent for 1.9 billion euros
www.reuters.com - April 17 at 8:47 AM
Sanofi to Sell Generics for $2.4 Billion to Focus on BiotechSanofi to Sell Generics for $2.4 Billion to Focus on Biotech
www.bloomberg.com - April 17 at 8:47 AM
[$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion[$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion
finance.yahoo.com - April 17 at 8:47 AM
Sanofi (SNY) Downgraded by BidaskClub to SellSanofi (SNY) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - April 16 at 5:24 PM
Sanofi SA (SNY) Expected to Post Earnings of $0.84 Per ShareSanofi SA (SNY) Expected to Post Earnings of $0.84 Per Share
www.americanbankingnews.com - April 16 at 5:14 PM
Advent Near Deal to Buy Sanofis (SNY) Generics Unit - BloombergAdvent Near Deal to Buy Sanofi's (SNY) Generics Unit - Bloomberg
www.streetinsider.com - April 16 at 8:29 AM
Advent Is Said to Near Deal to Acquire Sanofi Generics UnitAdvent Is Said to Near Deal to Acquire Sanofi Generics Unit
finance.yahoo.com - April 16 at 8:29 AM
Frances Sanofi sells 12 brands to Charterhouses Cooper-VemediaFrance's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia
finance.yahoo.com - April 16 at 8:29 AM
Sanofi (SNY) Rating Reiterated by Deutsche BankSanofi (SNY) Rating Reiterated by Deutsche Bank
www.americanbankingnews.com - April 16 at 8:17 AM
FY2018 Earnings Estimate for Sanofi SA Issued By Jefferies Group (SNY)FY2018 Earnings Estimate for Sanofi SA Issued By Jefferies Group (SNY)
www.americanbankingnews.com - April 16 at 2:27 AM
Sanofi (SNY) Receives "Market Perform" Rating from CowenSanofi (SNY) Receives "Market Perform" Rating from Cowen
www.americanbankingnews.com - April 14 at 3:07 PM
Advent leads race to buy Sanofis generics armAdvent leads race to buy Sanofi's generics arm
www.ft.com - April 14 at 8:38 AM
[$$] Advent International closes in on deal for Sanofi’s generics unit[$$] Advent International closes in on deal for Sanofi’s generics unit
finance.yahoo.com - April 14 at 8:38 AM
[$$] Advent leads race to buy Sanofi’s generics arm[$$] Advent leads race to buy Sanofi’s generics arm
finance.yahoo.com - April 14 at 8:38 AM
Sanofi to invest €350 million in Canadian vaccine facilitySanofi to invest €350 million in Canadian vaccine facility
finance.yahoo.com - April 12 at 8:58 AM
Healthcare group Sanofi to invest 350 mln euros in Canada vaccine facilityHealthcare group Sanofi to invest 350 mln euros in Canada vaccine facility
finance.yahoo.com - April 12 at 8:58 AM
New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levelsNew tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels
finance.yahoo.com - April 12 at 8:58 AM
Sanofi Stock Performance in 1Q18Sanofi Stock Performance in 1Q18
finance.yahoo.com - April 10 at 5:19 PM
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE ...PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE ...
globenewswire.com - April 5 at 10:30 AM
New Sanofi insulin savings program aims to lower out-of-pocket costs for people living with diabetesNew Sanofi insulin savings program aims to lower out-of-pocket costs for people living with diabetes
finance.yahoo.com - April 5 at 10:30 AM
Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EUSanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU
finance.yahoo.com - April 4 at 8:34 AM
Regeneron (REGN) & Sanofi (SNY) Report EMA to Review Cemiplimab as Potential Treatment for Advanced ...Regeneron (REGN) & Sanofi (SNY) Report EMA to Review Cemiplimab as Potential Treatment for Advanced ...
www.streetinsider.com - April 3 at 8:38 AM
Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinomaSanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
finance.yahoo.com - April 3 at 8:38 AM
European Medicines Agency to review Sanofi-Regenerons Dupixent, CemiplimabEuropean Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab
finance.yahoo.com - April 3 at 8:38 AM
Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthmaSanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
finance.yahoo.com - April 3 at 8:38 AM
How Eli Lilly’s Cardiovascular Products Performed in 4Q17How Eli Lilly’s Cardiovascular Products Performed in 4Q17
finance.yahoo.com - April 2 at 8:57 AM
Sanofis (SNY) Neutral Rating Reiterated at Nord/LBSanofi's (SNY) Neutral Rating Reiterated at Nord/LB
www.americanbankingnews.com - March 31 at 1:34 PM
 Analysts Expect Sanofi SA (SNY) Will Post Earnings of $0.84 Per Share Analysts Expect Sanofi SA (SNY) Will Post Earnings of $0.84 Per Share
www.americanbankingnews.com - March 30 at 7:10 PM
Sanofi to commence previous tender offers to acquire Ablynx on April 4Sanofi to commence previous tender offers to acquire Ablynx on April 4
seekingalpha.com - March 29 at 8:42 AM
Does Sanofi’s (EPA:SAN) Debt Level Pose A Problem?Does Sanofi’s (EPA:SAN) Debt Level Pose A Problem?
finance.yahoo.com - March 29 at 8:42 AM
Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetesSanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes
finance.yahoo.com - March 29 at 8:42 AM
Is Regeneron Pharmaceuticals, Inc. a Buy?Is Regeneron Pharmaceuticals, Inc. a Buy?
finance.yahoo.com - March 29 at 8:42 AM
Sanofi SA (SNY) Receives Average Rating of "Hold" from BrokeragesSanofi SA (SNY) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 29 at 1:52 AM
Sanofi: FDA Approves Toujeo Max SoloStar Pen - Quick FactsSanofi: FDA Approves Toujeo Max SoloStar Pen - Quick Facts
www.nasdaq.com - March 27 at 8:43 AM
Sanofi (SNY) Lifted to "Buy" at Liberum CapitalSanofi (SNY) Lifted to "Buy" at Liberum Capital
www.americanbankingnews.com - March 23 at 10:50 AM
Sanofi Target of Unusually High Options Trading (SNY)Sanofi Target of Unusually High Options Trading (SNY)
www.americanbankingnews.com - March 16 at 8:02 AM
What Analysts Recommend for AstraZeneca in March 2018What Analysts Recommend for AstraZeneca in March 2018
finance.yahoo.com - March 14 at 6:50 PM
Traders Buy High Volume of Put Options on Sanofi (SNY)Traders Buy High Volume of Put Options on Sanofi (SNY)
www.americanbankingnews.com - March 14 at 6:49 AM
Regeneron Takes Aim at Amgen and Esperion TherapeuticsRegeneron Takes Aim at Amgen and Esperion Therapeutics
finance.yahoo.com - March 13 at 8:40 AM
In Cholesterol Drug Battle, Sanofi/Regeneron Jolt Prospects Of The Medicines Company And EsperionIn Cholesterol Drug Battle, Sanofi/Regeneron Jolt Prospects Of The Medicines Company And Esperion
finance.yahoo.com - March 12 at 10:48 AM
Regeneron discounts on cholesterol drug sends some rival stocks downRegeneron discounts on cholesterol drug sends some rival stocks down
finance.yahoo.com - March 12 at 10:48 AM
Regeneron and Sanofi Announce Positive Data on PraluentRegeneron and Sanofi Announce Positive Data on Praluent
finance.yahoo.com - March 12 at 10:48 AM
Deutsche Bank Reaffirms Buy Rating for Sanofi (SNY)Deutsche Bank Reaffirms Buy Rating for Sanofi (SNY)
www.americanbankingnews.com - March 12 at 10:47 AM
Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death ratePraluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
finance.yahoo.com - March 11 at 8:30 AM

SEC Filings

Sanofi (NYSE:SNY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sanofi (NYSE:SNY) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sanofi (NYSE SNY) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.